Positron emission tomography (PET) constitutes a functional imaging technique that is
harnessed to probe biological processes in vivo. PET imaging has been used to diagnose …

Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT),
Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of …

Positron emission tomography with selective radioligands advances the drug discovery and
development process by revealing information about target engagement, proof of …

This review describes general concepts with regard to radiopharmaceuticals for diagnostic
or therapeutic applications that help to understand the specific challenges encountered …

Positron emission tomography (PET) plays key roles in drug discovery and development, as
well as medical imaging. However, there is a dearth of efficient and simple radiolabeling …

Is the 67Cu production worldwide feasible for expanding preclinical and clinical studies?
How can we face the ingrowing demands of this emerging and promising theranostic …

The lack of efficient [18F] fluorination processes and target-specific organofluorine
chemotypes remains the major challenge of fluorine-18 positron emission tomography …

We report the first one-pot formal alkene carboradiofluorination reaction employing easily
accessible alkenes as both prosthetic group precursors and coupling partners. The …

While the development of positron emission tomography (PET) radiopharmaceuticals
closely follows that of traditional drug development, there are several key considerations in …